KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Gains from Sales and Divestitures (2016 - 2026)

CRISPR Therapeutics AG (CRSP) has disclosed Gains from Sales and Divestitures for 10 consecutive years, with $736238.0 as the latest value for Q4 2025.

  • Quarterly Gains from Sales and Divestitures rose 63.35% to $736238.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $736238.0 through Dec 2025, up 63.35% year-over-year, with the annual reading at $736238.0 for FY2025, 63.35% up from the prior year.
  • Gains from Sales and Divestitures hit $736238.0 in Q4 2025 for CRISPR Therapeutics AG, up from $590587.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $736238.0 in Q4 2025 to a low of $109355.0 in Q1 2021.
  • Historically, Gains from Sales and Divestitures has averaged $309757.3 across 5 years, with a median of $272278.5 in 2023.
  • Biggest five-year swings in Gains from Sales and Divestitures: soared 2087.1% in 2021 and later tumbled 47.76% in 2022.
  • Year by year, Gains from Sales and Divestitures stood at $455440.0 in 2021, then crashed by 47.76% to $237932.0 in 2022, then rose by 16.76% to $277808.0 in 2023, then surged by 62.23% to $450701.0 in 2024, then surged by 63.35% to $736238.0 in 2025.
  • Business Quant data shows Gains from Sales and Divestitures for CRSP at $736238.0 in Q4 2025, $590587.0 in Q3 2025, and $501884.0 in Q2 2025.